Omni Bio Pharmaceutical — Equity Micro-Cap Conference (September 2009)
30 slides from Omni Bio Pharmaceutical's conference presentation, Sep 29, 2009

Slide 1: Omni Bio Pharmaceutical, Inc (OTCBB:OMBP)
Pharmaceutical, Inc (OTCBB:OMBP) dited Members, Inc lL Equity Micro-Cap Conference

Slide 2: Forward-Looking Statements
Forward-Looking Statements Except for the historical information contained herein, the matters discussed in this presentation are forward-looking statements. The forward-looking statements in this presentation are based on information avaiable to us as of the date any such statements are made and we

Slide 3: Pioneering the Discovery, Development, and Commercialization of Alternative Therapies
Pioneering the Discovery, Development, and Commercialization of Alternative Therapies for Diabetes, Bacterial and Viral Disease, and Transplant Rejection

Slide 4: Omni is positioned to take advantage of large markets with unmet medical needs
Omni is positioned to take advantage of large markets which have unmet medical needs at the present time > Type 1 Diabetes-Approximately 2 million patients in the US alone, potential $5-10 billion market. Total Current Market size for Diabetes drugs and services (type 1 and 2) of $92 billion per Can

Slide 5: Omni Bio's Objectives
Omni Bio’s Objectives » To develop, patent, and commercialize new indications in potentially large markets, for drugs that have received previous FDA approval for other indication(s) » By utilizing drugs with existing approvals, new indications will be able to piggy-back on the safety record of the

Slide 6: Omni Bio Overview
Omni Bio Overview Omni Bio becamea Public Company on March 31, 2009 when it completed a reverse merger and financing for $1.87 million, provided by institutional investors Omni is the licensee of three patent portfolios from the University of Colorado related to: Patent applications for the Treatmen

Slide 7: Omni is the licensee of filed patent applications owned by the University of Colorado
~-Omni is the licensee of filed patent 7" applications owned by the University of Colorado ° These filed patents include the method of use for the treatment of diabetes utilizing AAT * Our strategy is to sub-license the patents to one or more producers of AAT, many of whom are major pharmaceutical c

Slide 8: Management
~ Management Acting Chief Executive Officer-Charles A. Dinarello, MD (Yale) Member of the National Academy of Sciences -Listed by Institute for Scientific Information as the world’s fourth most clted scientist for 20 years fig82-2003). Numerous international awards including 2009 Crafoord Prize (Swe

Slide 9: Principal Investigator at the University of Colorado, Anschutz Medical Center
Principal Investigator at the University of Colorado, Anshutz Medical Center Dr. Leland Shapiro, MD , FACP Associate Professor of Medicine University of Colorado Certified by American Board of Internal Medicine University of Massachusetts School of Medicine Broadly published researcher Dr. Shapiro i

Slide 10: Scientific Advisory Board
~ Scientific Advisory Board © Dr. Michael Iseman-National Jewish Hospital and Professor at the University of Colorado. Dr. Iseman isa prominent international expert on tuberculosis, particularly, and drug resistant tuberculosis. Dr. James Crapo- National Jewish Hospital and Professorat the Universit

Slide 11: What is Alpha Antitrypsin (AAT)?
——— “What is Alpha 1 Antitrypsin (AAT)? * AATisa naturally occurring human serum protein. AAT is currently EDA approved and prescribed for emphysema and chronic obstructive pulmonary disorder in AAT deficient patients. Omnis three licenses relate to new discoveries for the use of AAT in the treatmen

Slide 12: Method for Treatment of Type 1 Diabetes
iethod for atment of Type 1 Diabetes A previously approved trial of AAT for off-label use will potentially allow human clinical trials in Type 1 diabetes patients.

Slide 13: Institutional Review Board Submission
Institutional Review Board Submission Omni Bio and a prominent research hospital are nearing initial Institutional Review Board (IRB) approval to conduct the first trial of AAT in recently diagnosed Type 1 diabetes in children and adolescents (specifically Office for Human Research Protections). An

Slide 14: Type 1 Diabetes (aka Juvenile Diabetes)
SS Type 1 Diabetes (aka Juvenile Diabetes) © ‘Type 1 Diabetes occurs when the body's immune system attacks and destroys certain cells in the panereas, The cells, called beta cells, normally produce insulin, however when beta cells are destroyed no insulin can be produced, causing the uncontrolled gl

Slide 15: Basis of Type 1 Diabetes Therapy Thesis
Basis of Type 1 Diabetes Therapy Thesis * Inmice, AAT protects the insulin-producing beta cells against toxic agents e AAT has been demonstrated to protect HUMAN islet cells against toxic effects of inflammatory cytokines. Inflammatory cytokines are produced in type 1 diabetes and are the cause of c

Slide 16: AAT has received previous FDA approval for use in human pancreatic islet transplantation
AT has received previous FDA approval for the use of AAT in human pancreatic islet transplantation Precedent has been established for the testing of AAT in humans on off-label fields of use * Omni has submitted a proposal to the regional Institutional Review Board to approve the protocol on a propos

Slide 17: Market Size
~ Market Size 5 proximately 2 million Type 1 Diabetics and 22 million Type 2 Diabetics have been diagnosed in the US' (if only $1,000 per patient of AAT were provided annually this could infer toa potential $24 billion market) Approximately 8% of the US population has diabetes, and if trends continu

Slide 18: How Does AAT Work?
How Does AAT Work? Anti-Inflammatory Inhibits Enzymes such as proteinase-3 Anti-Migratory Anti-Complement Prevents maturation of antigen presentation Induces T-regulatory cells Inhibits responses to inflammatory cytokine Increases production of anti-inflammatory molecules

Slide 19: Pecan Islets: Effect of cytokine stimulation and protection by AAT
Pecan Islets: Effect of cytokine stimulation and protection by AAT TLap/IENy + ILap/IFNy AAT

Slide 20: Influenza
~ Influenza © The Influenza Pandemic of 1918 caused an estimated 20-100 million deaths Worldwide, with approximately 675,000 American deaths, a number that was approximately 10X larger than our WWI casualties ° The effect of the pandemic was so severe that the average life expectancy in the US was r

Slide 21: A : Z A
3 A 8 8 : Z A 2

Slide 22: Effect of AAT on Flu Production at Day 3 In Vitro
Effect of AAT on Flu Production at Day 2 In Vitro Fluaiene AAT 3ne/m AAT Ing/nL. **p<0.0004, ***p<0.0001 compared to 100% i

Slide 23: AAT protects cells from flu infection
AAT protects cells from flu infection

Slide 24: Survival: Mice exposed to FLU
Survival: Mice exposed to FLU (statistically significant, p=0.0007) 100° Percent survival o 2 4 6 8 10 12 14 16

Slide 25: Proof of Concept: AAT deficiency is a risk factor for FLU infection
Proof of Concept: AAT deficiency is a risk factor for FLU infection

Slide 26: AAT Therapy for FLU
AAT Therapy for FLU Current FLU treatments are of modest efficacy. There is an unmet need. . Use as both treatment and prophylaxis Should have efficacy for all Flu types including “bird FLU’, “Swine Flu (HiN1)”, and “weaponized” FLU AAT therapy impervious to mutation-induced resistance Compatible wi

Slide 27: AAT Technologies: Status
AAT Technologies: Status Indication Laboratory | Animal Human | Clinical trial studiesin | studies studies cells Anthrax s + - NA FLU + + A 7 Diabetes + ry + Pending Graft rejection + + 2 Pending Tuberculosis + + > - (vB) HIV a NA * 2 += completed or in process; -= has not been completed

Slide 28: Corporate Information
Corporate Information Symbol: OMBP (OTCBB) Fiscal Year End: March 31 Last Trade (9.25.2009): $13.50 Balance Sheet as of June 30, 20 Amount Cash and Equivalents $1,062,058, Total Assets 17,813 Total Liabilities 7o2,621 Stockholders Equity 495162 Working Capital 405,376 Common Stock 26,795,770 Warrant

Slide 29: Business Summary
Business Summary » Broad Intellectual Property Position In Major Markets Diabetes Influenza 3 Licenses

Slide 30: Thank you for your interest
Source: SEC EDGAR · 8-K filed Sep 29, 2009
More decks from Omni Bio Pharmaceutical Inc
Investor Presentation (September 2014)27 slides · Sep 11, 2014
Investor Presentation (June 2014)26 slides · Jun 3, 2014
Investor Presentation (September 2013)24 slides · Sep 9, 2013
Investor Presentation (July 2013)27 slides · Jul 2, 2013
Investor Presentation (February 2013)20 slides · Feb 12, 2013
Investor Presentation (March 2012)25 slides · Mar 20, 2012